Following the results of the SELECT trial, the FDA approved a new indication for Wegovy (semaglutide) in March 2024: to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight
The therapeutic dose of semiglutide (Ozempic/Wegovy) for weight loss is 2.4 mg
The Juventas Wellness team of board-certified internal medicine physicians brings years of experience and a deep commitment to your well-being
However, its important to note that about 22% of reported Byetta cases have involved serious side effects
This is because: GLP-1 agonists: Slow gastric emptying, enhance insulin secretion, regulate hepatic glucose Amylin agonists: Suppress appetite centrally, slow gastric emptying via distinct pathways Together: Complementary mechanisms produce additive/synergistic effects on weight loss Cagrilintide Monotherapy Trials Initial clinical development focused on establishing the safety, tolerability, and efficacy of cagrilintide as a standalone therapy for weight management
